CD33 and myelodysplastic syndrome: Our studies demonstrated that cell lines derived from patients with MDS/AML or AML with erythroid features are generally less sensitive to gemtuzumab and PBD-conjugated ADCs targeting CD33 and CD123, compared to AML cell lines from patients with de novo or good- to intermediate-risk disease.